Skip to content
Search

Latest Stories

Covid test makers pull devices due to new review

Two producers of Covid-19 tests in Britain said on Tuesday (November 2) they had pulled some of their tests from the market after a new review system came into force, which has not yet granted approval for their previously accepted products.

Avacta said under the new system suppliers of Covid-19 tests had to submit information regarding their products for desktop review if they wished to remain on sale in Britain. It said it had submitted its information ahead of the September 1 deadline and was still waiting for a response.


As a result it has suspended further sales of its AffiDX SARS-CoV-2 Lateral Flow Rapid Antigen Test in the UK.

France-based Novacyt said it had submitted 11 products for review before the deadline. Two have appeared on a temporary UK list that can continue to be sold, but it is waiting for an update on the additional nine products.

Avacta said the new review system was "over and above" the European Union's CE health and safety mark and the successful registration with the UK's health regulator which it had previously achieved.

No one at the UK Health Security Agency was immediately available to comment.

The two companies said only three products had been fully approved while a temporary list allows 48 tests, both PCR and antigen based, to remain on sale.

Britain is carrying out higher levels of testing than many other countries in Europe, and is currently seeing around 40,000 cases of Covid-19 a day.

More For You

GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less
Community Pharmacy Scotland secures £10m reimbursement uplift amid ongoing negotiations

Negotiations continue on the Global Sum element of remuneration.

Getty Images

Community Pharmacy Scotland secures £120m reimbursement deal for 2025/26

Community Pharmacy Scotland (CPS) has accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

The agreement marks the first phase of ongoing negotiations surrounding community pharmacy funding for the upcoming financial year.

Keep ReadingShow less